D‐penicillamine in the treatment of rheumatoid arthritis

Open Access
Publisher Website
Google Scholar
Abstract
Forty‐four patients with definite or classic rheumatoid arthritis and failure to tolerate or respond to gold therapy were treated with D‐penicillamine on a so‐called go‐slow, go‐low regime. Seventeen patients tolerated the drug and had a 3−13 month follow‐up assessment; 8 were markedly improved, 6 moderately or slightly improved, and 3 unimproved. Penicillamine had to be discontinued in 9 patients because of toxic side effects.